Karyopharm Therapeutics

Karyopharm, Ono ink $193M deal

Friday, October 13, 2017

Karyopharm Therapeutics and Ono Pharmaceutical announced their entry into an exclusive license agreement for the development and commercialization of selinexor, Karyopharm’s lead, novel, oral Selective Inhibitor of Nuclear Export (SINE) compound, and KPT-8602, Karyopharm’s second-generation oral SINE compound. The agreement includes the development of selinexor and KPT-8602 for the diagnosis, treatment and/or prevention of all human oncology indications in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries (the Territory).

[Read More]

Karyopharm announces results from interim analysis of phase II SOPRA study

Friday, March 3, 2017

Karyopharm Therapeutics, a clinical-stage pharmaceutical company, has announced the results of a planned interim analysis of the phase II SOPRA study evaluating single agent selinexor in relapsed/refractory acute myeloid leukemia (AML). The company determined in concert with the study’s independent Data Safety Monitoring Board (DSMB) that SOPRA will not reach statistical significance for overall survival (OS), the study’s primary endpoint.

[Read More]

Karyopharm Therapeutics enters agreement with Clinipace Worldwide

Thursday, April 10, 2014

Clinipace Worldwide, a global digital CRO (dCRO), has announced that Karyopharm Therapeutics, a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology and wound healing.

[Read More]

Karyopharm Therapeutics secures $10 million in Seires A2 financing

Wednesday, November 2, 2011

Karyopharm Therapeutics has completed a $10M Series A2 financing which complements the $20M Series A financing announced one year ago. Both Series A and A2 were lead by Chione. This brings the total raised by the company to approximately $32M since its inception. The funds will be used to expand the planned phase I program, targeted to begin in mid 2012 with Karyopharm’s oral selective inhibitors of nuclear export (SINE) for various cancers. The company is also evaluating related transport modulators for use in dermatologic, inflammatory, and viral disorders.

[Read More]